Log in

Relevant bibliographies by topics / Infections à Francisella – Chimiothérapie

Contents

Journal articles
Dissertations / Theses
Books
Book chapters

Academic literature on the topic 'Infections à Francisella – Chimiothérapie'

Author: Grafiati

Published: 4 June 2021

Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Infections à Francisella – Chimiothérapie.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Infections à Francisella – Chimiothérapie"

1

Snoeck, R., and E. De Clercq. "La chimiothérapie des infections a cytomégalovirus." Médecine et Maladies Infectieuses 18 (March 1988): 79–84. http://dx.doi.org/10.1016/s0399-077x(88)80102-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Birkbeck, T. H., S. W. Feist, and D. W. Verner - Jeffreys. "Francisella infections in fish and shellfish." Journal of Fish Diseases 34, no. 3 (2011): 173–87. http://dx.doi.org/10.1111/j.1365-2761.2010.01226.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Haug, Rangdi Holth, and Andrew D. Pearson. "HUMAN INFECTIONS WITH FRANCISELLA TULARENSIS IN NORWAY." Acta Pathologica Microbiologica Scandinavica Section B Microbiology and Immunology 80B, no. 2 (2009): 273–80. http://dx.doi.org/10.1111/j.1699-0463.1972.tb00160.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ahmad, Saira, Lyman Hunter, Aiping Qin, Barbara J. Mann, and Monique L. van Hoek. "Azithromycin effectiveness against intracellular infections of Francisella." BMC Microbiology 10, no. 1 (2010): 123. http://dx.doi.org/10.1186/1471-2180-10-123.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Colquhoun, Duncan J., and Samuel Duodu. "Francisella infections in farmed and wild aquatic organisms." Veterinary Research 42, no. 1 (2011): 47. http://dx.doi.org/10.1186/1297-9716-42-47.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ingrand, Didier. "Chimiothérapie des infections à CMV et résistance aux antiviraux." Revue Française des Laboratoires 2002, no. 345 (2002): 57–62. http://dx.doi.org/10.1016/s0338-9898(02)80266-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Appelt, Sandra, Mirko Faber, Kristin Köppen, Daniela Jacob, Roland Grunow, and Klaus Heuner. "Francisella tularensis Subspecies holarctica and Tularemia in Germany." Microorganisms 8, no. 9 (2020): 1448. http://dx.doi.org/10.3390/microorganisms8091448.

Full text

Abstract:

Tularemia is a zoonotic disease caused by Francisella tularensis a small, pleomorphic, facultative intracellular bacterium. In Europe, infections in animals and humans are caused mainly by Francisella tularensis subspecies holarctica. Humans can be exposed to the pathogen directly and indirectly through contact with sick animals, carcasses, mosquitoes and ticks, environmental sources such as contaminated water or soil, and food. So far, F. tularensis subsp. holarctica is the only Francisella species known to cause tularemia in Germany. On the basis of surveillance data, outbreak investigations, and literature, we review herein the epidemiological situation—noteworthy clinical cases next to genetic diversity of F. tularensis subsp. holarctica strains isolated from patients. In the last 15 years, the yearly number of notified cases of tularemia has increased steadily in Germany, suggesting that the disease is re-emerging. By sequencing F. tularensis subsp. holarctica genomes, knowledge has been added to recent findings, completing the picture of genotypic diversity and geographical segregation of Francisella clades in Germany. Here, we also shortly summarize the current knowledge about a new Francisella species (Francisella sp. strain W12-1067) that has been recently identified in Germany. This species is the second Francisella species discovered in Germany.

APA, Harvard, Vancouver, ISO, and other styles

8

Peng, Kaitian, and Denise M. Monack. "Indoleamine 2,3-Dioxygenase 1 Is a Lung-Specific Innate Immune Defense Mechanism That Inhibits Growth of Francisella tularensis Tryptophan Auxotrophs." Infection and Immunity 78, no. 6 (2010): 2723–33. http://dx.doi.org/10.1128/iai.00008-10.

Full text

Abstract:

ABSTRACT Upon microbial challenge, organs at various anatomic sites of the body employ different innate immune mechanisms to defend against potential infections. Accordingly, microbial pathogens evolved to subvert these organ-specific host immune mechanisms to survive and grow in infected organs. Francisella tularensis is a bacterium capable of infecting multiple organs and thus encounters a myriad of organ-specific defense mechanisms. This suggests that F. tularensis may possess specific factors that aid in evasion of these innate immune defenses. We carried out a microarray-based, negative-selection screen in an intranasal model of Francisella novicida infection to identify Francisella genes that contribute to bacterial growth specifically in the lungs of mice. Genes in the bacterial tryptophan biosynthetic pathway were identified as being important for F. novicida growth specifically in the lungs. In addition, a host tryptophan-catabolizing enzyme, indoleamine 2,3-dioxygenase 1 (IDO1), is induced specifically in the lungs of mice infected with F. novicida or Streptococcus pneumoniae. Furthermore, the attenuation of F. novicida tryptophan mutant bacteria was rescued in the lungs of IDO1−/− mice. IDO1 is a lung-specific innate immune mechanism that controls pulmonary Francisella infections.

APA, Harvard, Vancouver, ISO, and other styles

9

Zhou, Hua, Qing Yang, Lisha Shen, et al. "Seawater-Associated Highly Pathogenic Francisella hispaniensis Infections Causing Multiple Organ Failure." Emerging Infectious Diseases 26, no. 10 (2020): 2424–28. http://dx.doi.org/10.3201/eid2610.190844.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Brudal, E., L. S. Ulanova, E. O. Lampe, A. L. Rishovd, G. Griffiths, and H. C. Winther-Larsen. "Establishment of Three Francisella Infections in Zebrafish Embryos at Different Temperatures." Infection and Immunity 82, no. 6 (2014): 2180–94. http://dx.doi.org/10.1128/iai.00077-14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Infections à Francisella – Chimiothérapie"

1

Maruejouls, Christophe. "Etat actuel de la sensibilité aux antibiotiques des "Pasteurella" et bactéries apparentées isolées d'infections humaines." Paris 5, 1995. http://www.theses.fr/1995PA05P194.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Attrait, Xavier. "Septicémies à Pasteurella Multocida : à propos de quatre cas et revue de la littérature." Bordeaux 2, 1999. http://www.theses.fr/1999BOR2M038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Fabre, David. "Approche pharmacocinétique de l'antibiothérapie dans les infections pulmonaires." Montpellier 1, 1995. http://www.theses.fr/1995MON13504.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Brandely, Marie-Laure. "Nouvelles prises en charge des principales infections fongiques hospitalières : évaluation pharmaco-économique." Paris 5, 1999. http://www.theses.fr/1999PA05P183.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Zupanc, Kauss Tina. "Intérêt thérapeutique et formulation galénique des polyphénols dans le traitement des infections et inflammations." Bordeaux 2, 2007. http://www.theses.fr/2007BOR21501.

Full text

Abstract:

La réponse immune pro-inflammatoire peut parfois entraîner des processus pathologiques, comme la destruction de la matrice articulaire dans le cas de la polyarthrite rhumatoide ou une cachexie mortelle dans le cas de la trypanosomose africaine. Dans ces deux pathologies, des nouveaux traitements sont nécessaires pour une meilleure prise en charge des malades. Les flavonols, des molécules naturelles végétales peu toxiques, pourraient apporter cette alternative thérapeutique, mais leurs effets anti-inflammatoires et anti-parasitaires doivent être démontrés et/ou caractérisés. Notre travail consistait à évaluer le potentiel thérapeutique de deux flavonols : la quercétine et la rutine. Nous avons étudié leurs effets à des doses non toxiques pour les cellules humaines sur les médiateurs d'inflammation macrophagiques au niveau génomique et protéique. L'inhibition duTNFα, de l'IL1β et du NO a pu être mise en évidence in vitro. L'effet anti-inflammatoire a été confirmé in vivo sur un modèle d'arthrite chez le rat (un modèle proche de la polyarthrite rhumatoide humaine) où l'amélioration des scores cliniques et de la cachexie était corrélée à la diminution des marqueurs inflammatoires sériques. Par ailleurs, l'effet trypanocide de la rutine et de la quercétine a été démontré et étudié in vitro pour déterminer sa cinétque et les relations dose-réponse. De plus, l'effet trypanocide de la vitamine C a pu être démontré in vitro. Les études in vivo devront vonfirmer l'efficacité de ces molécules dans le cas de la trypanosomose africaine. Une première approche de développement galénique a été réalisée pour améliorer la biodisponibilité et donc les effets thérapeutiques des flavonols<br>Immune response can become a pathological process, leading to a joint matrix destruction in rheumatoid arthritis or to a chronic cachexia in African trypanosomosis. In both pathologies, new therapeutics are needed for a better patients care. Flavonols, non toxic vegetal compounds, could bring a therapeutic alternative in these diseases, but their anti-inflammatory and anti-parasitic effects should be proved and/or characterized. We evaluated therefore the therapeutic potential of two flavonols, quercetin and rutin, in view of their use in human medicine. The effects of non toxic doses of flavonols on macrophage inflammatory mediators' gene transcription and protein expression were studied. In vitro inhibition of TNFα? il1β and NO was also confirmed on rat adjuvant-induced arthritis model, showing a correlation between clinical signs of inflammation (clinical scores and cachexia) and serum inflammatory mediators. In addition, quercetin and rutin trypanocidal effects were demonstrated and the kinetics and dose-response relationship studied. Furthermore, the in vitro trypanocydal effect of vitamin C was highlighted. In vivo studies should confirm the effectiveness of these molecules in African trupanosomosis. A first galenic approach was also conducted in order to improve the bioavailability and consequent therapeutic effects of flavonols

APA, Harvard, Vancouver, ISO, and other styles

6

Oung, Nguon Pumngear. "Infections nosocomiales : intérêt du suivi des consommations d'antibiotiques." Paris 5, 1999. http://www.theses.fr/1999PA05P061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Couturier, Sarah. "Synthèse et étude de 3'-desoxy-3'-C-methylnucléosides pyrimidiques." Montpellier 2, 2004. http://www.theses.fr/2004MON20183.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Dupin, Valérie. "Chimiothérapie des infections à VIH et à Herpesviridae : modes d'action : mécanismes de résistances : revue de la littérature." Bordeaux 2, 1993. http://www.theses.fr/1993BOR2P017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Le, Moing Vincent. "Réponse virologique et immunologique aux traitements avec inhibiteurs de protéase chez les patients infectés par le VIH." Bordeaux 2, 2001. http://www.theses.fr/2001BOR28872.

Full text

Abstract:

Les traitements antirétroviraux avec inhibiteurs de protéase ont été largement prescrits avant d'avoir été complètement évalués. Cette thèse a pour principal but, grâce à l'étude dans une cohorte de patients traités de mesures répétées de marqueurs biologiques, la charge virale plasmatique (CV) et le taux de lymphocytes CD4, de montrer comment les études d'observation peuvent contribuer à répondre à deux questions en suspens concernant ces traitements : quand faut-il les débuter ? comment mesurer leur effet à court et moyen terme ? La réponse immuno-virologique semblait plus importante et durable chez les patients débutant le traitement à CV basse et lymphocytes CD4 élevés ce qui était en faveur d'une initiation précoce des traitements au cours de la maladie. Cependant, pour la question de l'indication des traitements, les études d'observation sont possiblement limitées par la présence de biais, seul un essai contrôlé permettrait d'y répondre de façon valide. L'analyse des relations entre réponse virologique et évolution des lymphocytes CD4 a permis d'introduire la notion de réponse virologique partielle, définie par une CV basse mais détectable, par opposition à la CV indétectable, habituellement considérée comme l'objectif du traitement : le taux de lymphocytes CD4 continuait d'augmenter après la survenue d'un échec virologique avec une CV < 5000 copies/ml. Une analyse préliminaire de la progression vers le SIDA durant les deux premières années de suivi semblait confirmer ce résultat : la progression était associée à une CV > 10000 copies-ml 4 mois après le début du traitement. Sous réserve de confirmation à plus long terme sur un plus grand nombre d'événements, ces résultats sont en faveur d'un objectif plus modeste des traitements antirétroviraux. En prenant en compte des variables socio-comportementales, l'adhérence au traitement ou la précarité, ces travaux ont également permis de souligner leur importance tant en épidémiologie qu'en pratique quotidienne<br>Protease inhibitor-containing antiretroviral regimens have been largely prescribed before a complete evaluation. The main objective of this thesis is to analyse repeated measures of two biological markers : plasma HIV RNA (VL) and CD4+cell counts (CD4) in a cohort of treated patients in order to show how observational studies may contribute to the answering to two pending questions concerning these treatments : when to start them ? how to measure their short and longer term efficacy ? The analyses of immunological and virological response yielded results favouring early initiation of therapy in the course of the disease : response was more frequent and more sustained when patients initiated therapy at low VL and high CD4. Due to the observational nature of the data, there are many potential biases however and only a controlled trial may answer to the question of the moment of initiation of therapy. The analyses of the relationships between virological response and further increase of CD4 suggested a potential role for partial virological response, i. E. Low but detectable VL as opposed to the complete virological response, undetectable VL, which is usually considered as the goal of therapy. In patients having virological failure with a VL < 5,000 copies/ml, a continuous increase of CD4 was observed. Preliminary analyses of progression to AIDS tended to confirm this result : progression was associated with a VL > 10,000 copies/ml 4 months after the initiation of therapy. If these results were confirmed with a longer follow-up and a higher number of events, they would be in favour of a more modest goal of therapy. Studies presented in this thesis also took into account sociological and behavioural measures, like adherence to therapy and social support and emphasised their important role, in epidemiology as well as in routine clinical practice

APA, Harvard, Vancouver, ISO, and other styles

10

Jarrige, Jean Marc. "La pharmacochimie de l'acyclovir et de ses analogues." Paris 5, 1989. http://www.theses.fr/1989PA05P005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Infections à Francisella – Chimiothérapie"

1

Dariosecq, Jean-Michel. Infection VIH: Mémento thérapeutique 2003. 6th ed. Doin, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Battling HIV/AIDS: A decision maker's guide to the procurement of medicines and related supplies. World Bank, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Jacques, Thèze, and Debré Patrice, eds. Le sida à l'ère des multithérapies. Elsevier, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Pearson, Andrew. Tularaemia. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198570028.003.0031.

Full text

Abstract:

Tularaemia is a plague-like bacterial disease of animals (particularly rodents, hares, and rabbits) and man caused by five subspecies of Francisella. Two subspecies predominate: F. tularensis tularensis in North America and F. tularensis holarctica throughout the northern hemisphere. F. tularensis occurs in persistent natural foci causing localized epidemics and sporadic cases in man.Francisella tularensis subspecies tularensis was described originally as causing a more virulent form of tularaemia than was seen in Europe. More recently recognized are subpopulations of Francisella tularensis subspecies tularensis which have markedly different virulence for man. These have been designated A1a, A1b and A2. Infections resulting from type A1b have been shown to have an attributable mortality of 24% as compared to 4% for tularaemia caused by A1a types.F. tularensis is one of the most potent bacterial pathogens affecting humans with an infective dose from 1 to 10 organisms. The incubation period is usually 3–5 days (range from 1–21 days). Onset of disease is abrupt, with fever, chills, fatigue, general body aches, and headache. When the bacteria are acquired through skin or mucous membranes, tender regional node enlargement may become conspicuous. When bacteria are inhaled, the infection will result in deep lymph node enlargement.The clinical epidemiology of human infection is complex since it relates to one of four modes of transmission of the agent harboured in multiple hosts from diverse ecosystems. Clinical presentation of the human disease is indicative of both the mode of transmission and often the source of infection in a specific ecosystem. Tularaemia presenting as ulceroglandular disease results from either vector-borne infection from mosquito or tick bites or occurs as a result of animal contact from bites, hunting or from skinning hares or muskrats. Oropharyhgeal and typhoidal infections predominate in waterborne outbreaks of F. tularensis holarctica. Pulmonary or influenza disease results from airborne transmission associated with either farmers moving rodent contaminated hay or laboratory acquired infection. An intentional aerosol release of F. tularensis tularensis would be expected to result in clinical manifestations similar to those recognized in natural respiratory tularaemia. Both vector-borne and airborne transmission of F. tularensis may both be associated with florid skin manifestations as a presenting symptom of tularaemia. Pulmonary or typhoidal forms of the tularaemia may occur as a complication of localized infection.

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Infections à Francisella – Chimiothérapie"

1

Bar-Haim, Erez, Hila Cohen, Raphael Ber, Ofer Cohen, and Avigdor Shafferman. "Consequences of Antibiotic Treatment of Francisella tularensis Airways Infections." In The Challenge of Highly Pathogenic Microorganisms. Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-9054-6_22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Memish, Ziad A., and Manuel W. Mah. "Less usual indications: Mycobacterial, Brucella, Yersinia, Francisella and other infections." In Milestones in Drug Therapy. Birkhäuser Basel, 2003. http://dx.doi.org/10.1007/978-3-0348-8103-6_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Iwen, Peter. "Francisella Infections." In xPharm: The Comprehensive Pharmacology Reference. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.60881-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Iwen, P. C. "Francisella Infections☆." In Reference Module in Biomedical Sciences. Elsevier, 2015. http://dx.doi.org/10.1016/b978-0-12-801238-3.05028-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Schaffner, William. "Tularemia and Other Francisella Infections." In Goldman's Cecil Medicine. Elsevier, 2012. http://dx.doi.org/10.1016/b978-1-4377-1604-7.00319-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!